SAN DIEGO, Feb. 1, 2016 /PRNewswire/ -- MEI Pharma, Inc.
(Nasdaq: MEIP), an oncology company focused on the clinical
development of novel therapies for cancer, announced today that
Daniel P. Gold, Ph.D., President and
Chief Executive Officer, will present at the BIO CEO & Investor
Conference on Monday, February 8,
2016 at 4:30 p.m. Eastern time
from the Waldorf Astoria New York. A live webcast of the
presentation can be accessed at www.meipharma.com. A replay will be
available approximately one hour after the presentation.
Logo - http://photos.prnewswire.com/prnh/20140805/133834
About MEI Pharma
MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on
the clinical development of novel therapies for cancer. The
Company's lead drug candidate is Pracinostat, a potential
best-in-class, oral HDAC inhibitor expected to enter a Phase III
registration study for the treatment of elderly patients with newly
diagnosed acute myeloid leukemia (AML) in the second half of 2016.
The Company's portfolio of drug candidates also includes ME-401
(formerly PWT143), a highly selective, oral PI3K delta inhibitor
expected to enter a Phase Ib study in B-cell malignancies in the
second quarter of 2016, and ME-344, a novel mitochondrial inhibitor
with evidence of clinical activity in refractory solid tumors. For
more information, please visit www.meipharma.com.
Under U.S. law, a new drug cannot be marketed until it has
been investigated in clinical studies and approved by the FDA as
being safe and effective for the intended use. Statements included
in this press release that are not historical in nature are
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ
materially from those contained in the forward-looking statements,
which are based on management's current expectations and are
subject to a number of risks and uncertainties, including, but not
limited to, our failure to successfully commercialize our product
candidates; costs and delays in the development and/or FDA
approval, or the failure to obtain such approval, of our product
candidates; uncertainties or differences in interpretation in
clinical trial results; our inability to maintain or enter into,
and the risks resulting from our dependence upon, collaboration or
contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and distribution
of any products; competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary rights to third
party patents and intellectual property to operate our business;
our inability to operate our business without infringing the
patents and proprietary rights of others; general economic
conditions; the failure of any products to gain market acceptance;
our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry
practice; and one-time events. We do not intend to update any of
these factors or to publicly announce the results of any revisions
to these forward-looking statements.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mei-pharma-to-present-at-bio-ceo--investor-conference-300212442.html
SOURCE MEI Pharma, Inc.